Characterisation of gastrointestinal and thoracic neuroendocrine tumours

被引：0

作者：

Baudin, E. ^{[1
]}

Scoazec, J. -Y. ^{[1
]}

Caramella, C. ^{[1
]}

Leboulleux, S. ^{[1
]}

Caron, O. ^{[1
]}

Deandreis, D. ^{[1
]}

Duvillard, P. ^{[1
]}

Lumbroso, J. ^{[1
]}

de Baere, T. ^{[1
]}

Deschamps, F. ^{[1
]}

Goere, D. ^{[1
]}

Dumont, F. ^{[1
]}

Elias, D. ^{[1
]}

Malka, D. ^{[1
]}

Boige, V. ^{[1
]}

Schlumberger, M. ^{[1
]}

Guigay, J. ^{[1
]}

Planchard, D. ^{[1
]}

Ducreux, M. ^{[1
]}

机构：

[1] Gustave Roussy, Ctr Expert RENATEN Tumeurs Neuroendocrines, F-94805 Villejuif, France

来源：

ONCOLOGIE | 2013年 / 15卷 / 10-11期

关键词：

Neuroendocrine tumours; Prognosis factors; Diagnostic impact; Characterisation; Response to treatment; Multidisciplinary expertise; RENATEN and TENPATH networks; ENETS CONSENSUS GUIDELINES; PROGNOSTIC-FACTORS; ENDOCRINE TUMORS; MANAGEMENT; NEOPLASMS;

D O I：

10.1007/s10269-013-2343-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Once the diagnosis of a neuroendocrine tumour has been made, characterisation is an essential step before therapy. It comes before the decision regarding treatment is made. This requires a multidisciplinary team of experts located in specialist centres that currently make up the RENATEN and TENPATH networks. It is directed by knowledge of the location of the primary tumour and anatomical pathological differentiation. The aim of this characterisation step is to highlight factors that may have an impact on the diagnosis and the prognosis or predict the response to treatment.

引用

页码：505 / 509

页数：5

共 50 条

[41] NEUROENDOCRINE TUMOURS
Travis, William
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S19 - S20
[42] Clinico-epidemiological Profile of Incidentally Detected Gastrointestinal Neuroendocrine Tumours on Gastrointestinal Endoscopy: A Retrospective Study
Koushik, Ak
Reddy, J. Sai Harish
Ganesh, P.
Shanmuganathan, S.
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2023, 17 (04) : OC09 - OC12
[43] Gastrointestinal neuroendocrine tumours. Prospective analysis of 29 patients and literature review
Wenisch, HJC
ZENTRALBLATT FUR CHIRURGIE, 2001, 126 (01): : 23 - 31
[44] Clinicopathological characteristics and long-term outcome of gastrointestinal neuroendocrine tumours in Germany
Maasberg, S.
Rinke, A.
Ezziddin, S.
Quietzsch, D.
Barth, C.
Pavel, M.
Weber, M.
Grabowski, P.
Bohle, W.
Pape, U. -F
ONKOLOGIE, 2010, 33 : 66 - 66
[45] Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours -: A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)
Plöckinger, U
Rindi, G
Arnold, R
Eriksson, B
Krenning, EP
de Herder, WW
Goede, A
Caplin, M
Wiedenmann, B
Öberg, K
Reubi, JC
Nilsson, O
Delle Fave, G
Ruszniewski, P
Ahlman, H
NEUROENDOCRINOLOGY, 2004, 80 (06) : 394 - 424
[46] Neuroendocrine tumours-challenges in the diagnosis and classification of pulmonary neuroendocrine tumours
den Bakker, M. A.
Thunnissen, F. B. J. M.
JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (10) : 862 - 869
[47] Development of a disease specific quality of life score questionnaire for patients with gastrointestinal neuroendocrine tumours
Davies, AHG
Ramage, JK
Friend, L
Jones, L
Ardill, J
Larsson, G
Falconi, M
Bettani, R
Koller, M
Sezer, O
Fleissner, C
Taal, B
GUT, 2005, 54 : A50 - A50
[48] Why did they change that? Practical implications of the evolving classification of neuroendocrine tumours of the gastrointestinal tract
Gill, Anthony J.
HISTOPATHOLOGY, 2021, 78 (01) : 162 - 170
[49] Symptomatic effect of a long acting Lanreotide formulation in patients with gastrointestinal neuroendocrine tumours.
Jacobsen, MB
deVries, EGE
Eriksson, B
Fiasse, R
Wijmenga, M
Salmela, P
Valimaki, M
Oberg, K
Renstrup, J
GASTROENTEROLOGY, 1996, 110 (04) : A535 - A535
[50] DOES SPECIALIST CENTRE HISTOPATHOLOGY REVIEW OF GASTROINTESTINAL NEUROENDOCRINE TUMOURS AFFECT CLINICAL MANAGEMENT?
Jones, S. C. Bowen
Foster, L.
Valle, J.
Mansoor, W.
Hubner, R.
Chakrabarty, B.
ANNALS OF ONCOLOGY, 2012, 23 : 381 - 381

← 1 2 3 4 5 →